Gilead Sciences Inc.’s Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a European cancer meeting on Friday.
https://www.pharmalive.com/wp-content/uploads/2020/07/Gileads-COVID-19-antiviral-remdesivir-gets-conditional-EU-clearance-Reuters-7-3-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-09-07 18:30:092022-09-07 23:00:57Gilead's Trodelvy extends breast cancer survival by 3.2 months - study
